All In Biotech

Investigational drug · Phase 3

matched to Povetacicept

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Immunoglobulin A Nephropathy.

Phase 3

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "matched to Povetacicept"

First trial start

2024

Aug 30, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "matched to Povetacicept", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Immunoglobulin A Nephropathy

Approved drugs for the same conditions: IgA nephropathy · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "matched to Povetacicept" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Immunoglobulin A Nephropathy

  • FelzartamabPhase 38 trials

    Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease

  • PovetaciceptALPN-303Phase 37 trials

    Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy

  • FUB523zigakibart, BION-1301Phase 36 trials

    Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)

  • MIL116Phase 21 trial

    Beijing Mabworks Biotech Co., Ltd. · Immunoglobulin A Nephropathy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.